Xeris Pharmaceuticals Inc. (XERS) Misses Q2 EPS by 19c; Offers Guidance

Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q2 EPS of ($0.18), $0.19 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $92.1 million versus the consensus estimate of $90.29 million.

GUIDANCE:

Xeris Pharmaceuticals Inc. sees FY2026 revenue of $385-390 million, versus the consensus of $385.9 million.

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.

You May Also Be Interested In

• Dyadic International, Inc. (DYAI) Misses Q2 EPS by 2c
• Dyadic posts wider Q2 loss as costs rise despite flat revenue
• CoreWeave (CRWV) Reiterated at Neutral by DA Davidson Amid Rising Cost of Capital